Kissei Pharmaceutical USPTO patentsUtility application

Utility

Gonadotropin-releasing Hormone Antagonist Dosing Regimens for Treating Uterine Fibroids and Reducing Menstrual Blood Loss

4 Jan 24

The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist.

Ernest LOUMAYE, Jean-Pierre GOTTELAND, Oliver POHL

Filed: 11 Sep 23

Utility

Succinate Salts of Octahydrothienoquinoline Compound and Crystals Thereof

14 Sep 23

An object of the present invention is to provide a compound which has high storage stability and is suitable for use as a drug substance.

Hideki TAKEUCHI, Kazumichi JO

Filed: 5 Jul 21

Utility

lkejujs 6azeh0s15nj4g99n

18 Aug 22

The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2.

Wiliam Owen WILKISON, Bentley CHEATHAM, James Trinca GREEN, Yoshikazu FUJIMORI

Filed: 1 Jun 20

Utility

i4ngbet uopcszjjodinezdesytahj76u7szxhw

7 Oct 21

An object of the present invention is to provide a novel formulation containing sucroferric oxyhydroxide, particularly a novel formulation that can be ingested without being chewed.

Homare Kurashima, Hiroaki Omori, Nobuyuki Isshiki

Filed: 9 Aug 19

Utility

8iohzz65oj3ber076gkcafcw896ndww8sajcy5i4axja58zoxogvn5w

15 Jul 21

The present invention aims to provide a novel compound which has prolyl hydroxylases (PHDs) inhibitory effect and which is useful for the treatment of inflammatory bowel diseases such as ulcerative colitis and the like.

Yasushi Takigawa, Yusuke Kawabe, Haruka Ohtsuki, Kyosuke Nakamura

Filed: 13 Sep 19

Utility

hgq2j38gcsnplnu21i4sdvzf6ycyu99lxjkozcjzc6 bx86tc2gsnc

8 Jul 21

Akihiro Moriyama, Yasushi Takigawa

Filed: 12 Sep 19

Utility

cfs3b75mz62dcnol5crcnno1u

18 Feb 21

An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis.

Takuro Dan, Hideomi Takahashi, Yu Kuramochi

Filed: 8 Apr 20

Utility

iltcqbqfjg74ow5xv20ky42o5f

16 Dec 20

The present invention provides 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyl-oxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt having excellent solubility and storage stability.

Kazumichi JO, Hideki TAKEUCHI

Filed: 20 Jan 20

Utility

8awquzdkhqitewx5r7ca5wtvmo9

23 Sep 20

Atsushi Kondo, Naohide Morita, Takehiro Ishikawa, Masako Yoshida, Akihiro Moriyama, Isao Wanajo

Filed: 19 Jul 17